Sepsis Diagnostics Market Size Worth USD 1077.6 Million in 2030| Emergen Research

The global sepsis diagnostics market size was USD 492.1 Million in 2021 and is expected to register a steady revenue CAGR of 9.0% during the forecast period, according to latest analysis by Emergen Research.

The sepsis diagnostics market has been growing significantly over the past few years, driven by increasing prevalence of sepsis, rising demand for rapid diagnostic tests, and advancements in technologies for diagnosing sepsis. Sepsis is a life-threatening condition that occurs when the body's immune system overreacts to an infection, leading to organ dysfunction and failure. Early diagnosis of sepsis is critical for successful treatment, and diagnostic tests play a vital role in the management of sepsis.

One of the major drivers of the sepsis diagnostics market is the increasing prevalence of sepsis worldwide. According to the World Health Organization (WHO), sepsis affects over 30 million people globally each year, leading to an estimated six million deaths annually. The increasing incidence of sepsis is driving demand for diagnostic tests that can help healthcare providers detect the condition early and initiate appropriate treatment.

Another key driver of the sepsis diagnostics market is the growing demand for rapid diagnostic tests. Rapid diagnostic tests provide results quickly, allowing healthcare providers to initiate appropriate treatment without delay. The availability of rapid diagnostic tests has improved the management of sepsis and reduced the risk of mortality. Furthermore, the growing adoption of point-of-care testing is also driving the demand for rapid diagnostic tests.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/1823

Despite the growth factors, the market faces certain challenges that may hinder its growth. One of the major challenges is the high cost associated with diagnostic tests for sepsis. Diagnostic tests for sepsis can be expensive, which limits their adoption in low-income countries. Furthermore, the lack of awareness and understanding of sepsis among healthcare providers and patients is also a major restraint for the market.

However, technological advancements in sepsis diagnostics are expected to create new growth opportunities in the market. For instance, the development of biomarkers and molecular diagnostic tests is expected to drive the growth of the market in the coming years. Furthermore, the increasing adoption of automated diagnostic systems and the integration of artificial intelligence (AI) in sepsis diagnostics are expected to create new growth opportunities in the market.

According to a report by the Centers for Disease Control and Prevention (CDC), sepsis is a leading cause of hospital readmissions in the United States. The report states that one in three patients who are hospitalized for sepsis is readmitted within 30 days of discharge. The high rate of hospital readmissions for sepsis underscores the need for better diagnostic tests and more effective treatment options for the condition.

Major Companies and Competitive Landscape:

The sepsis diagnostics market is highly competitive, with several players competing for market share. Some of the leading players in the market include BIOMÉRIEUX, BD, Danaher, T2 Biosystems, Inc., Luminex Corporation, F. Hoffmann-La Roche Ltd, Thermofisher Scientific, Bruker, and Abbott.

bioMérieux SA is a leading player in the sepsis diagnostics market, offering a range of diagnostic tests for sepsis. The company's VITEK 2 system is a popular choice among healthcare providers, as it provides rapid identification and susceptibility testing of microorganisms. In addition, bioMérieux SA's FilmArray system allows for the simultaneous detection of multiple pathogens associated with sepsis.

Becton, Dickinson and Company is another leading player in the sepsis diagnostics market. The company offers a range of diagnostic tests for sepsis, including the BD MAX System, which provides rapid and accurate detection of pathogens associated with sepsis. The company also offers the BD Veritor System, a rapid antigen test that can be used for the diagnosis of respiratory infections, including pneumonia.

Thermo Fisher Scientific Inc. is a major player in the sepsis diagnostics market, offering a range of diagnostic tests and instruments for the detection of sepsis. The company's sepsis diagnostic portfolio includes the Procalcitonin (PCT) assay, which is used for the diagnosis and management of sepsis. Thermo Fisher Scientific Inc. also offers the Thermo Scientific Sorvall ST 16 Centrifuge, which is used for the isolation of pathogens from blood samples.

Abbott Laboratories is another major player in the sepsis diagnostics market, offering a range of diagnostic tests for sepsis. The company's ARCHITECT i1000SR system is a popular choice among healthcare providers, as it provides rapid and accurate identification of pathogens associated with sepsis. In addition, Abbott Laboratories offers the Alinity m system, a high-throughput molecular diagnostic platform that can be used for the detection of sepsis.

T2 Biosystems, Inc. is a leading player in the sepsis diagnostics market, offering the T2Bacteria Panel and the T2Candida Panel for the rapid detection of bacteria and fungi associated with sepsis. The company's T2MR technology allows for the direct detection of pathogens in whole blood samples, providing rapid and accurate results.

Roche Diagnostics is another major player in the sepsis diagnostics market, offering a range of diagnostic tests and instruments for the detection of sepsis. The company's sepsis diagnostic portfolio includes the Elecsys BRAHMS PCT assay, which is used for the diagnosis and management of sepsis. Roche Diagnostics also offers the cobas 4800 system, a high-throughput molecular diagnostic platform that can be used for the detection of sepsis.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/1823

Segmentation Insights Sepsis Diagnostics Market Report:

Emergen Research has conducted a detailed segmentation analysis of the global sepsis diagnostics market, based on several key factors. The market has been segmented on the basis of technology, product, method, pathogen type, test type, end-use, and region.

In terms of technology, the sepsis diagnostics market has been segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. Among these, the blood culture segment is expected to account for a significant share of the market, owing to the high sensitivity and specificity of this method in detecting sepsis pathogens.

On the basis of product, the sepsis diagnostics market has been segmented into blood culture media, assays & reagent kits, instruments, and software. The assays & reagent kits segment is expected to account for a significant share of the market, owing to the high demand for these products in laboratory settings.

The sepsis diagnostics market has been segmented on the basis of method into conventional diagnostics and automated diagnostics. The automated diagnostics segment is expected to grow at a significant rate, owing to the increasing adoption of automated systems in laboratory settings.

Based on pathogen type, the sepsis diagnostics market has been segmented into bacterial sepsis, fungal sepsis, viral sepsis, and other pathogens. The bacterial sepsis segment is expected to account for a significant share of the market, owing to the high prevalence of bacterial infections that can lead to sepsis.

On the basis of test type, the sepsis diagnostics market has been segmented into laboratory tests and point-of-care tests. The laboratory tests segment is expected to account for a significant share of the market, owing to the high accuracy and sensitivity of these tests in detecting sepsis pathogens.

In terms of end-use, the sepsis diagnostics market has been segmented into hospitals and specialty clinics, pathology & reference laboratories, research laboratories, and other end-uses. The hospitals and specialty clinics segment is expected to account for a significant share of the market, owing to the high patient volume in these settings and the need for rapid and accurate sepsis diagnostics.

Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/sepsis-diagnostics-market

Eric Lee
Corporate Sales Specialist
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions.

This release was published on openPR.